What the Researchers Actually Did
More than a year after federal regulators declared the semaglutide and tirzepatide shortages over, compounded versions of the drugs behind Ozempic, Wegovy, Mounjaro and Zepbound are still being sold across storefront weight loss clinics and medical spas, according to a study published July 17 in JAMA Health Forum.